Renal Business Today

Erythropoietin-Stimulating Agents (ESAs)

DOPPS to Hold Web Conference, Release Hemodialysis Update

ANN ARBOR, Mich.—On Thursday, May 2 , at 3 p.m. EDT, Arbor Research Collaborative for Health, will host a Web conference featuring an update to the Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor (DPM). Participants interested in listening in on the ...More
3 weeks ago
Posted in News, Clinical & Pharma
Billing Solutions: Billing Self-Administered Epogen/ESA's

I understand we are supposed to bill self-administered Epogen for Medicare home dialysis patients, according to the medication schedule prescribed by the patient’s physician. However, some of the physicians only specify the number of times per week the patient is supposed ...More
March 12, 2013
Posted in Articles, Practice Management
Rockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study

WIXOM, Mich.—Rockwell Medical announced successful topline results from the PRIME clinical study of Soluble Ferric Pyrophosphate (SFP), its investigational iron-delivery drug currently in Phase 3 clinical studies for the treatment of iron deficiency in hemodialysis ...More
February 4, 2013
Posted in News, Clinical & Pharma
Rockwell Medical Announces Final Patient Dosed in Prime Clinical Study

WIXOM, Mich.—Rockwell Medical announced that patient dosing has completed in its PRIME clinical study, which is designed to investigate the reduction in the need for erythropoiesis stimulating agents (ESAs) in hemodialysis patients receiving Soluble Ferric Pyrophosphate ...More
January 7, 2013
Posted in News, Clinical & Pharma
GAO: Dialysis Bundle Payment Too High

The Government Accountability Office (GAO) released a report on December 7 entitled "End-Stage Renal Disease: Reduction in Drug Utilization Suggests Bundled Payment Rate is Too High." ...More
December 13, 2012
Posted in Articles, Government & Regulation
A New Way to Decrease ESA and Improve Iron Count

When kidneys fail, the production of erythropoietin, the hormone that drives the production of red blood cells, stops. As a result, patients are provided with dialysis and an erythropoietin-stimulating agent (ESA). During each dialysis session, a patient loses anywhere from ...More
November 16, 2012
Posted in Articles, Business, Clinical & Pharma
Affymax, Takeda Announce Analyses from Omontys Injection Phase 3 Dialysis Studies Presented at ASN

PALO ALTO, Calif. & DEERFIELD, Ill.—Affymax and Takeda Pharmaceuticals U.S.A. announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated Omontys (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the ...More
November 1, 2012
Posted in News, Clinical & Pharma
First in the World: Northwest Kidney Centers Hits the Big 5-0

In 1961, James Haviland, president of the King County Medical Society helped Belding Scribner receive a grant from the Heartford Foundation. On Jan. 1, 1962 the world's first out-of-hospital nonprofit community outpatient dialysis center opened its doors in the basement of ...More
October 31, 2012
Posted in Articles, Practice Management
Nephrologists Continue to Report High Omontys Awareness, Usage Remains Low

EXTON, Pa.—BioTrends Research Group has released findings from the second wave (W2) of its LaunchTrends: Omontys report. This report surveyed a total of 81 U.S. nephrologists about their current awareness, trial and usage of Affymax/Takeda's Omontys (peginesatide), an ...More
October 3, 2012
Posted in News, Business
Takeda and Affymax Announce Supply Agreement for Omontys with US Renal Care

DEERFIELD, Ill. & PALO ALTO, Calif.—Takeda Pharmaceuticals U.S.A. and Affymax, Inc. today announced that Takeda Pharmaceuticals America, Inc. has entered into a supply agreement for sourcing and supply of Omontys (peginesatide) Injection with U.S. Renal Care, Inc. and ...More
August 9, 2012
Posted in News, Business